Source-grounded facts extracted from NUTRA PHARMA CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
NUTRA PHARMA CORP engaged Astra Audit & Advisory as its auditor.
“On December 18, 2024, the Board approved the engagement of Astra Audit & Advisory (“AA”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.”
Marcum LLP resigned as auditor of NUTRA PHARMA CORP.
“On March 27, 2024, the Audit Committee of the Board of Directors (the “Committee”) of Nutra Pharma Corp. (the “Company”) received a letter indicating the resignation of Marcum LLP (“Marcum”) as the Company’s independent registered public accounting firm.”
Michael Flax was appointed as Chief Executive Officer, Director, Chairman of the Board and Chief Financial Officer at NUTRA PHARMA CORP.
“On March 20, 2024, our Board of Directors unanimously approved of the appointment of Michael Flax, DDS as our Chief Executive Officer, Director, Chairman of the Board and Chief Financial Officer.”
Rik J. Deitsch resigned as Chief Executive Officer, Director, Chairman of the Board, and Chief Financial Officer at NUTRA PHARMA CORP.
“On March 19, 2024, Mr. Deitsch submitted a letter of resignation to our Board of Directors and thereby resigned as Chief Executive Officer, Director, Chairman of the Board, and Chief Financial Officer of Nutra Pharma Corp., effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.